Schizophrenia is a chronic debilitating disorder. Currently over 70 million people worldwide are suffering from schizophrenia. Current treatment options (anti psychotics) are not sufficient to encompass all symptoms of schizophrenia and have a large side effect profile. Therefore, novel treatment options are urgently needed. Our research aims to establish the potential benefits of a high fat, and very low carbohydrate diet (Ketogenic diet) in acute and chronic mouse models of schizophrenia. The Ketogenic diet has been in use safely and effectively for over 100 years in the treatment of childhood refractory epilepsy and is currently being investigated in disorders such as Alzheimer's, Parkinson's, Brain cancer and others. Recent literature has suggested that an impaired cerebral glucose metabolism is associated with schizophrenia. Therefore we have proposed that a metabolic based approach, such as the Ketogenic diet, causes a shift to fatty acid metabolism providing an alternative fuel source to glucose.
Our research is ongoing. We have found that Ketogenic diet normalized all 3 symptoms of schizophrenia in a acute NMDA-receptor antagonist mouse model of schizophrenia.
The aim of this project is to participate in ongoing research in mouse models of schizophrenia by analysing facilitated mouse trials.
Supervisor: Zoltan Sarnyai and Ann Katrin Kraeuter
Husbandry starts Tuesday through Friday from 8-10 AM including tasks such as: